专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2018071837A1 RADIOFREQUENCY FIELD HYPERTHERMIA AND SOLID TUMOR IMMUNOMODULATION 审中-公开
标题翻译：射频热疗和固体肿瘤免疫治疗
公开(公告)号：WO2018071837A1
公开(公告)日：2018-04-19
申请号：PCT/US2017/056621
申请日：2017-10-13
申请人： BAYLOR COLLEGE OF MEDICINE
发明人： CORR, Stuart, James , NEWTON, Jared, M. , CURLEY, Steven, A. , SIKORA, Andrew, G.
IPC分类号： A61B18/18 , A61K41/00 , A61K39/395 , A61P35/00
摘要： Embodiments of the disclosure concern methods and compositions for treating cancer in an individual that includes combination therapy comprising radiofrequency therapy and immunotherapy. In specific embodiments, utilization of the radiofrequency therapy invokes the immune system of the individual to provide an environment at the tumor that is receptive to native immune system components of the individual, and/or exogenously provided immune system components. In specific cases, the radiofrequency therapy enhances T cell localization to the tumor.
摘要翻译：本公开的实施方案涉及用于治疗个体癌症的方法和组合物，其包括包含射频治疗和免疫疗法的组合疗法。在具体的实施方案中，射频治疗的利用调用个体的免疫系统以提供接受个体天然免疫系统组分和/或外源提供的免疫系统组分的肿瘤环境。在特定情况下，射频治疗可增强T细胞定位至肿瘤。

12. 发明申请

WO2018067847A1 STRUCTURE OF GII.4 NOROVIRUS PROTEASE -DESIGN OF BROAD-SPECTRUM PROTEASE INHIBITORS 审中-公开
标题翻译： GII.4诺夫病毒蛋白酶的结构 - 广谱蛋白酶抑制剂的设计
公开(公告)号：WO2018067847A1
公开(公告)日：2018-04-12
申请号：PCT/US2017/055387
申请日：2017-10-05
申请人： BAYLOR COLLEGE OF MEDICINE
发明人： PRASAD, B.v. V, Enkataram , ESTES, Mary, K. , SONG, Youngcheng
IPC分类号： A01N43/06 , A01N43/50 , A01N43/78 , A61K31/343 , A61K31/381 , A61K31/403
摘要： The present disclosure concerns inhibitors of Norovirus protease that are suitable for use against any genotype of Norovirus, including at least GII.4 Norovirus proteases. In particular embodiments, specific compositions are encompassed, including their use for prevention or treatment of Norovirus infection in an individual.
摘要翻译：本公开涉及诺沃克病毒蛋白酶的抑制剂，其适用于针对诺如病毒的任何基因型，包括至少GII.4诺沃克病毒蛋白酶。在具体的实施方案中，涵盖了特定的组合物，包括它们用于预防或治疗个体中的诺如病毒感染。

13. 发明申请

WO2018064602A1 CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE 审中-公开
标题翻译：具有降低的细胞毒性的用于病毒疾病的嵌合抗原接受者治疗
公开(公告)号：WO2018064602A1
公开(公告)日：2018-04-05
申请号：PCT/US2017/054556
申请日：2017-09-29
申请人： BAYLOR COLLEGE OF MEDICINE
发明人： KRUSE, Robert, Layne , BISSIG, Karl-Dimiter , GOTTSCHALK, Stephen, M.G. , SHUM, Thomas, C.T.
IPC分类号： C07K19/00 , C12N15/13 , A61P1/16 , A61P31/20
摘要： Embodiments of the disclosure encompass immunotherapy for Hepatitis B viral (HBV) infection in an individual in need thereof. The immunotherapy comprises one or more chimeric antigen receptors (CAR) that target a HBV antigen, including CAR molecules that utilize specific scFv antibodies. In certain cases, the CAR comprises one or more mutations to reduce binding to Fc receptors. In specific aspects, cells that express the CAR(s) have reduced cytotoxicity that is safer and/or beneficial to individuals that are immunocompromised.
摘要翻译：本公开的实施方案包括对有此需要的个体的乙型肝炎病毒（HBV）感染的免疫治疗。免疫疗法包含一种或多种靶向HBV抗原的嵌合抗原受体（CAR），包括利用特异性scFv抗体的CAR分子。在某些情况下，CAR包含一个或多个突变以减少与Fc受体的结合。在具体方面，表达CAR的细胞具有降低的细胞毒性，所述细胞毒性对免疫受损的个体更安全和/或有益。

14. 发明申请

WO2018049049A1 CLINICAL APPLICATION OF CELL FREE DNA TECHNOLOGIES TO NON-INVASIVE PRENATAL DIAGNOSIS AND OTHER LIQUID BIOPSIES 审中-公开
标题翻译：无细胞DNA技术在无创性早期诊断和其他液态生物中的临床应用
公开(公告)号：WO2018049049A1
公开(公告)日：2018-03-15
申请号：PCT/US2017/050510
申请日：2017-09-07
申请人： BAYLOR COLLEGE OF MEDICINE , BAYLOR GENETICS
发明人： WONG, Lee-Jun, C. , ZHANG, Jinglan , LI, Jianli , FENG, Yanming , BEAUDET, Arthur, L. , DAI, Hongzheng , GE, Xiaoyan , MEI, Hui , WANG, Guoli
IPC分类号： C12Q1/68 , C40B50/06 , C40B40/08 , C12N15/10
摘要： Embodiments of the disclosure include methods of prenatal testing using non-invasive means that identify single gene disorders. In specific embodiments the methods are non-invasive and employ tagging circulating cell-free fetal DNA from the biological mother with particular adaptors that employ unique barcodes, followed by steps to enrich targets and steps for thorough sequencing.
摘要翻译：本公开的实施方案包括使用识别单基因疾病的非侵入性手段进行产前检测的方法。在具体的实施方案中，所述方法是非侵入性的并且使用来自生物母亲的具有特定衔接子的循环无细胞胎儿DNA标记，所述特定衔接子使用独特的条形码，接着是富集目标和步骤以进行彻底测序的步骤。

15. 发明申请

WO2018044685A1 A NOVEL CHICKEN EGG-BASED METASTASIS MODEL FOR CANCER 审中-公开
标题翻译：一种新型的基于鸡蛋的癌变模型
公开(公告)号：WO2018044685A1
公开(公告)日：2018-03-08
申请号：PCT/US2017/048452
申请日：2017-08-24
申请人： BAYLOR COLLEGE OF MEDICINE
发明人： SIKORA, Andrew G. , PATHAK, Ravi , SAN MARTIN, Rebeca , ROWLEY, David R.
IPC分类号： A61K35/32 , G01N33/50 , C12M3/00 , C12N5/09
摘要： Embodiments of the present disclosure concern systems, methods, and compositions for both in vitro and in vivo models of metastases, such as bone metastases. In specific embodiments, there is a system comprising a source of bone cells, such as osteoblasts, and a source of cancer cells, wherein the bone cells and cancer cells are configured in a chamber or on a chick chorioallantoic membrane such that interaction between the cells is determined. In specific embodiments, the bone cells are comprised in an organoid comprising both mesenchymal stem cells and osteoblasts (although a naturally derived bone scaffold may be employed), and the cancer cells are comprised in an organoid comprising mesenchymal stem cells and the cancer cells.
摘要翻译：本公开的实施方案涉及用于转移的体外和体内模型（例如骨转移）的系统，方法和组合物。在具体的实施方案中，存在包含骨细胞来源（例如成骨细胞）和癌细胞来源的系统，其中骨细胞和癌细胞被配置在腔室中或鸡胚尿囊膜上，使得细胞之间的相互作用决心，决意，决定。在具体的实施方案中，骨细胞包含在包含间充质干细胞和成骨细胞的类器官中（尽管可以使用天然来源的骨支架），并且癌细胞包含在包含间充质干细胞和癌细胞的类器官中。 / p>

16. 发明申请

WO2017189901A1 SILENCING TRANSGENE EXPRESSION DURING VECTOR PRODUCTION 审中-公开
标题翻译：在载体生产期间沉默转基因表达
公开(公告)号：WO2017189901A1
公开(公告)日：2017-11-02
申请号：PCT/US2017/029933
申请日：2017-04-27
申请人： BAYLOR COLLEGE OF MEDICINE
发明人： NG, Philip , PALMER, Donna, J.
IPC分类号： A61K31/713 , A61K48/00 , C07H21/04 , C12N15/113 , C12N15/861 , C12N15/63 , G01N33/50 , G01N33/53
CPC分类号： A61K31/713 , C12N15/113 , C12N15/86 , C12N2740/16043 , C12N2740/16052
摘要： Embodiments of the disclosure concern particular vectors and their production in which transgenes are silenced through one or more untranslated sequences comprising a target sequence for a microRNA produced from the adenoviral associated RNA I (VA RNAI) (mivaRNAI) and/or a microRNA produced from the adenoviral VA RNAII (mivaRNAII). Examples of specific sequences are disclosed.
摘要翻译：本公开的实施方案涉及特定载体及其产生，其中转基因通过一个或多个非翻译序列沉默，所述一个或多个非翻译序列包含由腺病毒相关RNA I（VA RNAi）（mivaRNA I）产生的微RNA的靶序列，和/或由腺病毒VA RNAII（mivaRNAII）产生的微RNA。披露了特定序列的例子。

17. 发明申请

WO2017180902A1 ASPROSIN, A FAST-INDUCED GLUCOGENIC PROTEIN HORMONE 审中-公开
标题翻译： ASPROSIN，一种快速诱导的糖原蛋白激素
公开(公告)号：WO2017180902A1
公开(公告)日：2017-10-19
申请号：PCT/US2017/027467
申请日：2017-04-13
申请人： BAYLOR COLLEGE OF MEDICINE
发明人： CHOPRA, Atul , MOORE, David D.
IPC分类号： A61K39/395 , A61P1/14 , A61P3/04 , A61P3/08 , A61P3/10 , C07K14/47
摘要： Embodiments of the disclosure concern methods and compositions that relate to increasing or decreasing the weight (including, for example, by increasing or decreasing the adipose mass) in individuals in need thereof. Such methods and compositions, in particular embodiments, concern providing an effective amount of the hormone asprosin to increase adipose mass in an individual with insufficient adipose mass and providing an antibody or inhibitor of asprosin in an individual with obesity or diabetes, for example, to reduce adipose mass.
摘要翻译：本公开的实施方案涉及涉及在需要其的个体中增加或减少体重（包括例如通过增加或减少脂肪量）的方法和组合物。在具体的实施方案中，这些方法和组合物涉及提供有效量的激素白色脂肪肽以增加脂肪量不足的个体的脂肪量并且在患有肥胖或糖尿病的个体中提供白色脂肪的抗体或抑制剂例如以减少脂肪团。

18. 发明申请

WO2016196113A1 METHODS OF REDUCING OR PREVENTING INTIMAL DAMAGE CAUSED BY MECHANICAL STIMULATION OF ENDOTHELIAL CELLS 审中-公开
标题翻译：降低或预防机械刺激内皮细胞引起的实体损伤的方法
公开(公告)号：WO2016196113A1
公开(公告)日：2016-12-08
申请号：PCT/US2016/034066
申请日：2016-05-25
申请人： UNIVERSITY OF MARYLAND, BALTIMORE , THE USA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS , REMEDY PHARMACEUTICALS, INC.
发明人： SIMARD, J., Marc , JACOBSON, Sven
IPC分类号： A61K38/00 , C12N15/11 , A61K48/00 , A61K39/395 , A61K31/175 , A61K31/18
CPC分类号： C12N15/1138 , A61K31/05 , A61K31/132 , A61K31/196 , A61K31/64 , A61P9/00 , C12N2310/11 , C12N2310/315
摘要： Embodiments of the disclosure encompass methods and/or compositions for ameliorating or preventing intimal damage caused by mechanical stimulation of endothelial cells. The damage may be caused by use of a device within an artery, vein, or capillary of an individual, such as to remove a thrombus, an embolus or an atherosclerotic plaque in the vessel. Treatment and prevention embodiments concern therapeutically effective amounts of one or more antagonists of the SUR1- TRPM4 channel that is upregulated upon the mechanical stimulation.
摘要翻译：本公开的实施方案包括用于改善或预防由内皮细胞的机械刺激引起的内膜损伤的方法和/或组合物。损伤可能是由于使用个体的动脉，静脉或毛细血管内的装置，例如去除血管中的血栓，栓塞或动脉粥样硬化斑块引起的。治疗和预防实施方案涉及治疗有效量的在机械刺激时上调的SUR1-TRPM4通道的一种或多种拮抗剂。

19. 发明申请

WO2016172606A1 CD5 CHIMERIC ANTIGEN RECEPTOR FOR ADOPTIVE T CELL THERAPY 审中-公开
标题翻译： CD5基因抗原受体用于接受T细胞治疗
公开(公告)号：WO2016172606A1
公开(公告)日：2016-10-27
申请号：PCT/US2016/029014
申请日：2016-04-22
申请人： BAYLOR COLLEGE OF MEDICINE
发明人： MAMONKIN, Maksim , BRENNER, Malcolm K.
IPC分类号： C07K16/30 , C07K14/705 , A61K38/17 , A61K39/395 , A61K45/06 , C07K14/715
CPC分类号： A61K38/1774 , A61K35/17 , A61K39/395 , A61K45/06 , A61P35/02 , C07K14/7051 , C07K14/70521 , C07K14/715 , C07K16/2896 , C07K16/30 , C07K2317/622 , C07K2317/92 , C07K2317/94 , C07K2319/03 , C12N5/0636
摘要： Embodiments of the disclosure include methods and compositions related to immunotherapy that targets CD5. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor (CAR) that targets CD5 are contemplated, and uses thereof. In particular embodiments, the immune cells expressing the CAR do not commit fratricide to any great extent against T cells that express CD5 and which are endogenous to an individual receiving the immune cells.
摘要翻译：本公开的实施方案包括与靶向CD5的免疫治疗相关的方法和组合物。在具体实施方案中，考虑了旨在包含靶向CD5的嵌合抗原受体（CAR）的免疫细胞及其用途。在具体实施方案中，表达CAR的免疫细胞不会对表达CD5的T细胞有很大程度的免疫细胞，并且对于接受免疫细胞的个体是内源性的。

20. 发明申请

WO2016070119A1 SURVIVIN SPECIFIC T-CELL RECEPTOR TARGETING TUMOR BUT NOT T CELLS 审中-公开
标题翻译： SURVIVIN特异性T细胞受体靶向肿瘤，但不是T细胞
公开(公告)号：WO2016070119A1
公开(公告)日：2016-05-06
申请号：PCT/US2015/058452
申请日：2015-10-30
申请人： BAYLOR COLLEGE OF MEDICINE
发明人： SAVOLDO, Barbara , DOTTI, Gianpietro , ARBER BARTH, Caroline, Eva
IPC分类号： C12N5/10 , C07K14/705 , C07K14/725
CPC分类号： C12N5/0694 , C07K14/705 , C07K14/7051 , C12N5/0636 , C12N2510/00
摘要： Embodiments of the disclosure concern engineered T cell receptors that are specific for the survivin tumor antigen but do not have "on-target off tumor" toxicity. In particular embodiments, particular alpha and beta chains are utilized in engineered T cell receptors for cell therapy that have effective anti-tumor activity but lack fratricidal effects. Methods, compositions, and kits are provided herein.
摘要翻译：本公开的实施方案涉及对生存素肿瘤抗原特异性但不具有“靶向肿瘤”毒性的工程化T细胞受体。在具体实施方案中，特定的α和β链用于具有有效的抗肿瘤活性但缺乏自相残杀的作用的用于细胞治疗的工程化T细胞受体。本文提供了方法，组合物和试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式